Fig. 4: CircATXN1 Knockdown Enhances Partial EndMT In Vivo.
From: Regulation of partial endothelial-to-mesenchymal transition by circATXN1 in ischemic diseases
a RT-qPCR of circATXN1 in the heart of mice with non-injection or mice injection with 4 × 1011 VG and 8 × 1011 VG AAV circATXN1-sh, 3 weeks after AAV injection, with β-actin as the internal control (n = 6 mice per group). b Representative HE stained sections from the liver of mice with non-injection or mice injection with 4 × 1011 VG and 8 × 1011 VG AAV circATXN1-sh, 3 weeks after AAV injection, the black arrow showed multinucleated cells. c–f Serum AST, ALT, albumin and direct bilirubin of mice with non-injection or mice injection with 4 × 1011 VG and 8 × 1011 VG AAV circATXN1-sh, 3 weeks after AAV injection (n = 6 mice per group). g RT-qPCR of circATXN1 in the heart of mice with non-injection or mice injection with 1 × 1011 VG, 2 × 1011 VG and 4 × 1011 VG AAV circATXN1-sh, 1, 2, 4, 8, 12 weeks after AAV injection, with β-actin as the internal control (n = 6 mice per group). h Blood flow recovery assessed by laser Doppler ultrasound in mice administered AAV Scr-sh or AAV circATXN1-sh (n = 4 mice per group). i Immunohistochemistry stain for Vimentin in gastrocnemius muscle sections 7 days post-HLI (n = 6, scale bars = 100 μm). j Echocardiography of left ventricular ejection fraction (LVEF) at baseline and days 7, 14, and 28 post-MI (n = 6 mice per group). k Scar size measurement at 4 weeks post-MI (n = 6 mice per group, scale bar = 2 mm). l Comparison of survival rates between mice treated with AAV Scr-sh and AAV circATXN1-sh after myocardial infarction (n = 20 mice per group). m Immunohistochemistry stain for Vimentin in heart sections from the infarcted border zone 7 days post-MI. Scale bars = 100 μm. Statistical analysis: unpaired two-tailed Student t test for (k); ordinary one-Way ANOVA test for (c, d, e, f); two-Way ANOVA with multiple comparisons test for (h, j); Logrank test for (i).
